Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic Leukemia treated with dexrazoxane.
Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity. A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's disease. We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
|Main Author:||Barry, Elly.|
|Other Authors:||Vrooman, Lynda., Dahlberg, Suzanne., Neuberg, Donna., Asselin, Barbara., Athale, Uma., Clavell, Luis., Larsen, Eric., Moghrabi, Albert., Samson, Yvan., Schorin, Marshall., Cohen, Harvey., Lipshultz, Steven., Sallan, Stephen., Silverman, Lewis.|